Longitude Capital
  • ABOUT
  • TEAM
  • PORTFOLIO
  • NEWS
  • CONTACT
  • LP LOGIN
Select Page

Roche to acquire 89bio (ETNB) in deal valued up to ~$3.5B

by mariel | Sep 17, 2025 | Portfolio News

Roche entered into a definitive merger agreement to acquire 89bio, including $14.50/share cash at closing plus a contingent value right tied to milestones.

Kestra reports Q1 FY26 results; increases full-year FY26 revenue guidance

by mariel | Sep 11, 2025 | Portfolio News

Kestra reported ~$19M revenue in Q1 FY26 (+52% YoY), improved gross margin, and increased FY26 revenue guidance to $88M.

Mirum completes enrollment in Phase 2b VISTAS study of volixibat

by mariel | Sep 8, 2025 | Portfolio News

Mirum announced completion of enrollment in the Phase 2b VISTAS study of volixibat in PSC cholestatic pruritus; topline data expected in 2Q 2026.

Rapid Micro Biosystems enters five-year, $45M term loan facility

by mariel | Aug 12, 2025 | Portfolio News

Rapid Micro Biosystems entered into a five-year, $45 million term loan facility with $20 million funded at closing to strengthen financial flexibility.

Endeavor BioMedicines receives Orphan Drug Designation for taladegib (ENV-101) in IPF

by mariel | Jul 16, 2025 | Portfolio News

Endeavor announced Orphan Drug Designation from both the European Commission and U.S. FDA for taladegib (ENV-101) for idiopathic pulmonary fibrosis; the company is enrolling WHISTLE-PF (Phase 2b).

Kestra Medical Technologies Announces Inclusion in the Russell 2000® and Russell 3000® Indexes

by Carolyn Helms | Jun 23, 2025 | Portfolio News

BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank

by Carolyn Helms | Jun 17, 2025 | Portfolio News

Cohere Health’s Review Assist Accelerates Clinical Reviews for Health Plans with Precision AI

by Carolyn Helms | Jun 16, 2025 | Portfolio News

Sydnexis Announces European Commission Approval of SYD-101, the First and Only Pharmaceutical Treatment for Slowing the Progression of Pediatric Myopia

by Carolyn Helms | Jun 5, 2025 | Portfolio News

Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy

by Carolyn Helms | Jun 2, 2025 | Portfolio News

« Older Entries
Next Entries »

Media Contact

Maggie Jamison

mjamison@longitudecapital.com

650-854-5700

  • Facebook
  • X
  • RSS
footer-logo

LP Login

© 2026 Longitude Capital. All rights reserved.
  • Privacy Policy
  • Disclaimer